Asia Pacific Imaging Agents Market size crossed USD 1.9 billion in 2021 and is projected to showcase around 5.3% growth rate between 2022 and 2028. The market growth is due to the rapid increase in the prevalence of stroke cases across the region that increases the demand for imaging procedures and contrast agents. Furthermore, major companies in the Asia Pacific region are focusing on the development of new generation CT angiograms and MRI for accurate diagnosis and treatment decisions.

Get more details on this report - Request Free Sample PDF

Asia Pacific Market, By Product Type

Get more details on this report - Request Free Sample PDF

Asia Pacific Market, By Application

The neurology segment will grow at 5.2% CAGR during the forecast timeline, attributed to rising cases of Alzheimer’s disease across the region. For instance, according to the Alzheimer’s and Related Disorders Society of India (ARDSI), in 2020, approximately 5.3 million people above the age of 60 affected due to Dementia in India. Therefore, to detect similar diseases, molecular imaging is preferred, provides detailed images of the body at cellular and molecular level. Thus, positron emission tomography (PET) and single-photon emission computed tomography (SPECT) is used to measure physiological changes for detecting central nervous system disorders.

Asia Pacific Market, By End-use

The hospitals segment dominated over 42% Asia Pacific imaging agents market share 2021, due to rising adoption of advanced diagnostic systems by hospitals to detect and diagnose diseases coupled with increasing number of hospitals in Asia Pacific region. Moreover, emergency rooms provide quality care for patients who are experiencing more dangerous conditions, such as stroke, severe bleeding, trauma, and some types of infection is expected to drive the industry growth.

Asia Pacific Market, By Modality

The X-ray segments will witness CAGR of more than 5.1% from 2022 to 2028, owing to the rising demand for structural imaging and functional imaging procedure.  Structural imaging measures anatomical structure while functional imaging reveals changes in biological functions. For X-ray, iodinated molecules and barium-based contrast agents are widely used for diagnostic imaging methods. Also, X-ray imaging method widely supports medical and surgical treatment planning to treat tumours, blood clots, or blockage removal.

Asia Pacific Market, By Country

India imaging agents market was valued at USD 310 million in 2021, on account of rising cardiovascular diseases in the region. For instance, according to the Global Burden of Disease, in 2021, around 24.6% deaths were due to cardiovascular diseases in India. Moreover, increasing healthcare expenditure coupled with presence of presence of well-established local and international manufacturers in the area. For instance, General Electric Pharmaceuticals (Shanghai) Co., Ltd., is a GE Healthcare subsidiary that manufactures diagnostic pharmaceuticals (CT/MR contrast media) in China is one of the world's largest contrast media manufacturing facilities.

Competitive Industry Landscape

Prominent participants operating across the in the Asia Pacific imaging agents market include Bayer Healthcare Pharmaceuticals, Trivitron Healthcare, Guerbet Group, Bracco Diagnostics, Inc., GE Healthcare, Eli Lily, and Beijing Beilu Pharmaceutical Co Ltd.